The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

Juan Simon Rico-Mesa; Daniel Rosas; Ashkan Ahmadian-Tehrani; Averi White; Allen S. Anderson; Robert Chilton

doi:10.1007/s11886-020-01328-8

The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

Juan Simon Rico-Mesa, Daniel Rosas, Ashkan Ahmadian-Tehrani, Averi White, Allen S. Anderson, Robert Chilton

Division of Cardiology

Research output: Contribution to journal › Review article › peer-review

70 Scopus citations

Abstract

Purpose of Review: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. Recent Findings: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. Summary: COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.

Original language	English (US)
Article number	53
Journal	Current Cardiology Reports
Volume	22
Issue number	7
DOIs	https://doi.org/10.1007/s11886-020-01328-8
State	Published - Jul 1 2020

Keywords

Anticoagulation
COVID-19
Hypercoagulability
SARS-CoV-2

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11886-020-01328-8

Cite this

@article{737b674b76b64662b06de2c2ba589649,

title = "The Role of Anticoagulation in COVID-19-Induced Hypercoagulability",

abstract = "Purpose of Review: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. Recent Findings: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. Summary: COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.",

keywords = "Anticoagulation, COVID-19, Hypercoagulability, SARS-CoV-2",

author = "Rico-Mesa, {Juan Simon} and Daniel Rosas and Ashkan Ahmadian-Tehrani and Averi White and Anderson, {Allen S.} and Robert Chilton",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = jul,

day = "1",

doi = "10.1007/s11886-020-01328-8",

language = "English (US)",

volume = "22",

journal = "Current Cardiology Reports",

issn = "1523-3782",

publisher = "Current Medicine Group",

number = "7",

}

TY - JOUR

T1 - The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

AU - Rico-Mesa, Juan Simon

AU - Rosas, Daniel

AU - Ahmadian-Tehrani, Ashkan

AU - White, Averi

AU - Anderson, Allen S.

AU - Chilton, Robert

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Purpose of Review: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. Recent Findings: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. Summary: COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.

AB - Purpose of Review: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. Recent Findings: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. Summary: COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.

KW - Anticoagulation

KW - COVID-19

KW - Hypercoagulability

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85086577259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086577259&partnerID=8YFLogxK

U2 - 10.1007/s11886-020-01328-8

DO - 10.1007/s11886-020-01328-8

M3 - Review article

C2 - 32556892

AN - SCOPUS:85086577259

SN - 1523-3782

VL - 22

JO - Current Cardiology Reports

JF - Current Cardiology Reports

IS - 7

M1 - 53

ER -

The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this